Sporadic Degenerative Ataxia With Adult Onset: Natural History Study

Last updated: June 28, 2017
Sponsor: Ataxia Study Group
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dyskinesias

Friedreich's Ataxia

Spinocerebellar Disorders

Treatment

N/A

Clinical Study ID

NCT02701036
SPORTAX 010/05
  • Ages > 40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The key goals of SPORTAX-NHS is to compare the phenotype of multiple system atrophy of cerebellar type (MSA-C) and sporadic adult onset ataxia of unknown aetiology (SAOA) and to determine the rate of disease progression in both groups including determination of the factors that predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.

The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Progressive ataxia

  • Disease onset after the age of 40 years

  • Informative and negative family history (no similar disorders in first- andsecond-degree relatives; parents older than 50 years, or, if not alive, age at deathof more than 50 years, no consanguinity of parents)

Exclusion

Exclusion Criteria:

  • No established acquired cause of ataxia Clinical exclusion criteria:

  • No onset of ataxia in association with stroke, encephalitis, sepsis, hyperthermia orheat stroke;

  • no chronic diarrhea;

  • no unexplained visual loss;

  • no alcohol abuse;

  • no chronic intake of anticonvulsant drugs;

  • no other toxic causes; no malignancies;

  • no rapid progression (development of severe ataxia in less than 12 weeks);

  • no insulin-dependent diabetes mellitus Imaging exclusion criteria:

  • No evidence of multiple sclerosis, ischemia, hemorrhage or tumor of the posteriorfossa;

  • absence of signal abnormalities on T2/FLAIR-images except abnormalities compatiblewith MSA Laboratory exclusion criteria:

  • Negative molecular genetic testing for FRDA (only required if there is no cerebellaratrophy on MRI, SCA1, SCA2, SCA3, SCA6, FMR1 premutation (only required if prominenttremor, cognitive impairment and signal abnormality on T2/FLAIR images in the middlecerebellar peduncle);

  • antineuronal antibodies negative (only required, if disease duration less than 3years);

  • normal levels of vitamin B12;

  • VDRL negative;

  • normal thyreoid function

Study Design

Total Participants: 300
Study Start date:
April 01, 2010
Estimated Completion Date:
December 31, 2030

Study Description

Progressive ataxia frequently starts in adults without a familial background. These patients may suffer from an acquired ataxia or a genetically determined ataxia despite negative family history. In the majority of them, however, a genetic or acquired cause of ataxia cannot be identified suggesting a sporadic degenerative ataxia. They can be subdivided into two groups. In one group, the underlying brain disease is multiple system atrophy (MSA), specifically MSA of cerebellar type (MSA-C). The characteristic clinical feature of MSA is the presence of severe autonomic failure defined by orthostatic hypotension or urinary incontinence. The second group is distinguished from MSA-C by the lasting absence of severe autonomic failure. These patients have been designated as sporadic adult onset ataxia of unknown aetiology (SAOA). In the first years after ataxia onset, a distinction between MSA-C and SAOA is often not possible.

There are only few studies comparing the phenotype of MSA-C and SAOA, and longitudinal studies focussing on the evolution of the phenotype of these disorders are completely lacking. In particular, the progression rate of SAOA compared to MSA-C has not been defined. In addition, it is unknown which factors predict the development of MSA-C vs. SAOA, and at which time after onset of ataxia, a reliable distinction between both disorders is possible.

To answer these questions, we plan to create a European registry of patients with sporadic degenerative ataxia of adult onset and to perform a natural history study. The planned study will also allow to collect blood samples and other biomaterials from patients with sporadic ataxia, which will be useful for future genetic and biomarker studies.

Connect with a study center

  • Department of Neurology, Medical University, Innsbruck

    Innsbruck,
    Austria

    Site Not Available

  • Universitätsmedizin Berlin Charité

    Berlin,
    Germany

    Active - Recruiting

  • Department of Neurology, University of Bonn

    Bonn, 53105
    Germany

    Active - Recruiting

  • Department of Neurology, University Clinic Essen, University of Duisburg-Essen

    Essen,
    Germany

    Active - Recruiting

  • Department of Neurology, University of Frankfurt

    Frankfurt,
    Germany

    Active - Recruiting

  • Hamburg UKE Abt. Neuropädiatrie

    Hamburg,
    Germany

    Site Not Available

  • Otto-von-Guericke Universität Magdeburg

    Magdeburg,
    Germany

    Active - Recruiting

  • Friedrich-Baur-Institut an der Neurologischen Klinik

    München,
    Germany

    Active - Recruiting

  • Universitätsmedidzin Rostock - Klinik und Poliklinik für Neurologie

    Rostock,
    Germany

    Active - Recruiting

  • Dept. of Neurodegenerative Diseases Tübingen

    Tübingen,
    Germany

    Active - Recruiting

  • Department of Neuroscience, Federico II University Naples

    Naples,
    Italy

    Active - Recruiting

  • Universita cattolica del sacro cuore

    Rome,
    Italy

    Site Not Available

  • Radboud University Medical Center, Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour

    Nijmegen,
    Netherlands

    Site Not Available

  • Oslo University Hospital

    Oslo,
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.